Novo Nordisk AS (LTS:0QIU)
kr 305.85 +3.55 (+1.17%) Market Cap: 1.36 Tn Enterprise Value: 1.45 Tn PE Ratio: 11.03 PB Ratio: 6.61 GF Score: 80/100

Q2 2026 Novo Nordisk A/S Earnings Call Transcript

Aug 05, 2026 / 11:00AM GMT
Operator

Good day, and thank you for standing by. Welcome to the Q2 2026 Novo Nordisk A/S earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Michael Novod, Head of Investor Relations. Please go ahead.

Michael Novod;S;Head of Investor Relations
Novo Nordisk A

/-

Thank you very much, operator. Welcome to this Novo Nordisk earnings call for the second quarter of 2026. My name is Michael Novod, and I'm the Head of Investor Relations at Novo Nordisk. With me today, I have CEO of Novo Nordisk, Mike Doustdar; EVP US Operations, Jamey Millar; EVP International Operations, Emil Kongshoej Larsen; EVP Research and Development and Chief Scientific Officer, Martin Holst Lange; and Chief Financial Officer, Karsten Munk Knudsen.

All speakers will be available for the Q&A session. Today's call is being webcasted live, and a recording will be made available on our website. The call is scheduled to last one

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot